INmune Bio, Inc.
INMB
$7.32
$0.010.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -63.16% | -71.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -63.16% | -71.13% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -- | -- | -63.16% | -71.13% |
| SG&A Expenses | -11.92% | -14.19% | 21.78% | 0.43% | 3.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.61% | 43.34% | 52.78% | 70.73% | 46.49% |
| Operating Income | -12.98% | -44.07% | -53.88% | -71.52% | -48.51% |
| Income Before Tax | -9.63% | -41.22% | -49.92% | -68.68% | -44.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.63% | -41.22% | -49.92% | -68.68% | -44.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.63% | -41.22% | -49.92% | -68.68% | -44.15% |
| EBIT | -12.98% | -44.07% | -53.88% | -71.52% | -48.51% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 11.17% | -25.99% | -39.33% | -67.93% | -43.54% |
| Normalized Basic EPS | 11.18% | -25.98% | -39.36% | -67.97% | -43.57% |
| EPS Diluted | 11.17% | -25.99% | -39.33% | -67.93% | -43.54% |
| Normalized Diluted EPS | 11.18% | -25.98% | -39.36% | -67.97% | -43.57% |
| Average Basic Shares Outstanding | 23.44% | 12.09% | 7.59% | 0.45% | 0.42% |
| Average Diluted Shares Outstanding | 23.44% | 12.09% | 7.59% | 0.45% | 0.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |